SOPHiA GENETICS SA

NasdaqGS SOPH

SOPHiA GENETICS SA EBITDA for the year ending December 31, 2023: USD -70.70 M

SOPHiA GENETICS SA EBITDA is USD -70.70 M for the year ending December 31, 2023, a 14.48% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

SOPHiA GENETICS SA EBITDA for the year ending December 31, 2022 was USD -82.67 M, a -16.70% change year over year.
SOPHiA GENETICS SA EBITDA for the year ending December 31, 2021 was USD -70.84 M, a -82.77% change year over year.
SOPHiA GENETICS SA EBITDA for the year ending December 31, 2020 was USD -38.76 M, a -26.08% change year over year.
SOPHiA GENETICS SA EBITDA for the year ending December 31, 2019 was USD -30.74 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: SOPH

SOPHiA GENETICS SA

CEO	Dr. Jurgi Camblong M.B.A., Ph.D.
IPO Date	July 23, 2021
Location	Switzerland
Headquarters	Rue du Centre 172
Employees	430
Sector	Technology
Industries Software-as-a-Service (SaaS) Telehealth

Description

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Key trends

Past 5 years